MUC16 and central nervous system cancer: The identification of features such as MUC16 (already in use in the clinic albeit not in the glioma setting) and GRIN2A and CIC, both relatively novel, as evidenced by current ingenuity pathway analysis (IPA) (Figure 4) [41], is not currently employed in the clinic but shows promise in analyzing mechanistic progression to higher grade and showcasing the clinical promise of novel applications such as GradWise as potential tools to identify novel biomarker in existing datasets such as TCGA and CGGA.